GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Q

Qingdao Vland Biotech 603739.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

11.71

-1.26%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.37bn

FY2016FY2025

Net income

CN¥69.8m

FY2016FY2025

Free cash flow

CN¥33.9m

FY2016FY2025

Shareholders' equity

CN¥1.78bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.37bnCN¥1.32bnCN¥1.20bnCN¥1.16bnCN¥1.15bnCN¥960.2mCN¥846.8mCN¥814.0mCN¥799.4mCN¥781.2m
Gross profitCN¥612.0mCN¥592.3mCN¥550.4mCN¥500.3mCN¥530.4mCN¥464.6mCN¥409.5mCN¥404.4mCN¥415.2mCN¥425.7m
Research and developmentCN¥139.2mCN¥121.3mCN¥110.7mCN¥102.4mCN¥100.9mCN¥79.9mCN¥75.0mCN¥69.7mCN¥70.6mCN¥77.5m
Operating incomeCN¥134.1mCN¥124.0mCN¥122.9mCN¥102.9mCN¥172.8mCN¥142.1mCN¥97.8mCN¥113.6mCN¥117.8mCN¥94.7m
Net incomeCN¥69.8mCN¥62.6mCN¥80.7mCN¥69.8mCN¥132.6mCN¥109.0mCN¥77.8mCN¥83.4mCN¥85.6mCN¥82.6m
Diluted earnings per share0.240.270.320.240.520.410.340.520.530.29

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥3.04bnCN¥2.98bnCN¥3.03bnCN¥2.58bnCN¥2.22bnCN¥1.45bnCN¥1.28bnCN¥945.3mCN¥883.5mCN¥827.9m
Cash and short-term investments—CN¥448.1mCN¥531.6mCN¥425.9mCN¥482.3mCN¥347.4mCN¥357.0mCN¥159.7mCN¥175.3mCN¥130.2m
Total liabilitiesCN¥1.13bnCN¥1.11bnCN¥1.21bnCN¥844.9mCN¥536.2mCN¥336.2mCN¥249.0mCN¥313.9mCN¥291.0mCN¥270.0m
DebtCN¥59.8mCN¥595.6mCN¥631.0mCN¥523.2mCN¥235.9mCN¥67.8mCN¥36.9mCN¥105.0mCN¥75.0mCN¥30.0m
Shareholders' equityCN¥1.78bnCN¥1.74bnCN¥1.71bnCN¥1.64bnCN¥1.60bnCN¥1.03bnCN¥962.2mCN¥569.7mCN¥544.3mCN¥516.5m
Shares outstanding286m236m254m295m255m263m226m160m162m286m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥113.9mCN¥195.4mCN¥153.6mCN¥95.3mCN¥89.5mCN¥173.0mCN¥65.3mCN¥85.8mCN¥121.9mCN¥154.5m
Capital spending−CN¥80.0m−CN¥104.7m−CN¥215.6m−CN¥342.0m−CN¥493.6m−CN¥211.8m−CN¥120.2m−CN¥71.6m−CN¥58.0m−CN¥26.5m
Free cash flowCN¥33.9mCN¥90.7m−CN¥62.1m−CN¥246.7m−CN¥404.1m−CN¥38.8m−CN¥54.8mCN¥14.2mCN¥63.9mCN¥127.9m
Dividends paid−CN¥43.0m−CN¥55.2m−CN¥39.8m−CN¥40.3m−CN¥36.0m−CN¥30.9m−CN¥30.9m−CN¥62.3m−CN¥60.6m−CN¥53.9m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥364.6mCN¥345.1mCN¥350.3mCN¥363.6mCN¥342.0mCN¥310.2mCN¥375.1mCN¥336.4m
Gross profitCN¥159.0mCN¥152.6mCN¥160.5mCN¥156.7mCN¥157.2mCN¥137.6mCN¥174.6mCN¥144.5m
Operating incomeCN¥40.9mCN¥35.9mCN¥31.2mCN¥55.6mCN¥29.4mCN¥24.6mCN¥41.6mCN¥27.2m
Net incomeCN¥20.7mCN¥17.9mCN¥8.0mCN¥35.1mCN¥17.1mCN¥9.6mCN¥21.8mCN¥11.5m
Diluted earnings per share0.070.060.030.120.060.030.090.05
Cash from operations———CN¥24.0mCN¥2.0mCN¥7.0m—CN¥18.0m
Capital spending−CN¥8.0m−CN¥14.0m−CN¥36.0m−CN¥7.0m−CN¥5.0m−CN¥41.0m−CN¥41.0m−CN¥6.0m
Free cash flow———CN¥17.0m−CN¥3.0m−CN¥34.0m—CN¥12.0m
Total assetsCN¥3.02bnCN¥3.08bnCN¥3.04bnCN¥3.04bnCN¥2.95bnCN¥3.03bnCN¥2.98bnCN¥3.03bn
Cash and short-term investments———CN¥438.8mCN¥350.2mCN¥472.0mCN¥448.1mCN¥500.6m
DebtCN¥49.9mCN¥50.1mCN¥59.8mCN¥673.4mCN¥578.2mCN¥668.6mCN¥595.6mCN¥717.2m
Shareholders' equityCN¥1.80bnCN¥1.80bnCN¥1.78bnCN¥1.77bnCN¥1.74bnCN¥1.75bnCN¥1.74bnCN¥1.73bn

Financial ratios

Data as of 20 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin44.8%44.8%45.9%43.0%46.1%48.4%
Operating margin10.4%11.1%11.5%9.4%15.1%14.8%
Net margin5.1%4.7%6.7%6.0%11.5%11.3%
Return on equity3.9%3.6%4.7%4.2%8.3%10.5%
Return on assets2.3%2.1%2.7%2.7%6.0%7.5%
Free cash flow yield5.4%10.1%11.6%11.8%18.3%11.7%
Revenue growth3.4%10.2%3.1%1.1%19.8%13.4%
Earnings growth11.5%-22.4%15.6%-47.3%21.7%40.2%
Current ratio1.17x1.04x1.03x1.50x2.61x2.72x
Debt to equity0.03x0.34x0.37x0.32x0.15x0.07x
Equity ratio58.6%58.3%56.3%63.8%72.2%71.2%
Interest coverage7.87x6.42x9.05x11.96x64.93x52.43x
R&D as a share of sales10.2%9.2%9.2%8.8%8.8%8.3%
Buybacks as a share of market value-21.2%7.1%13.9%-15.8%3.2%-16.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.5%7.3%6.2%
Operating income9.2%-1.2%7.0%
Net income-0.0%-8.5%-0.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin44.8%44.7%45.4%47.5%
Operating margin9.6%9.6%11.2%11.6%
Net margin4.9%5.6%7.3%8.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings58.145.248.056.835.838.853.1
Price to sales3.02.13.23.44.14.44.9

Dividends and splits

Per share, in the currency the company pays

Paid for 7 years. Last went ex-dividend on 29 May 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.100.100.100.100.160.1430.1430.143
  • 7-for-5 split · 25 May 2021

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.